{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-24-000097","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.469098+00:00","generated_at":"2026-05-31T11:38:15.808985+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"ClearPoint Neuro Q2 revenue $7.9M (+32% YoY); raises FY2024 guidance to $30-33M","bullets":["Record quarterly revenue of $7.9M, up 32% YoY; product revenue more than doubled to $4.9M.","Gross margin improved to 63% from 53% a year ago; operating cash burn reduced 47% to $2.7M.","Raised FY2024 revenue guidance to $30-33M from prior; cash position $32.8M after public offering.","Activated 6 new global centers in Q2 (14 YTD); SmartFrame OR and Prism Laser Therapy launched.","Seven pharma partners received expedited FDA review; SmartFlow Cannula approved in Taiwan."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-24-000097","json":"https://secwatch.observer/filing/0001285550-24-000097.json","markdown":"https://secwatch.observer/filing/0001285550-24-000097.md","text":"https://secwatch.observer/filing/0001285550-24-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000097/0001285550-24-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000097/clpt-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:38:15.808985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}